EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY
机构：[1]Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China[2]Jiujiang NO.1 People’s Hospital, Department of Rheumatology, Jiujiang, China[3]First Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China[4]People’s Hospital of Xinjiang Uygur Autonomous Region, Department of Rheumatology, Urumchi, China[5]West China Hospital of Sichuan University, Department of Rheumatology, Chengdu, China四川大学华西医院[6]Chenzhou First People’s Hospital, Department of Nephrology, Chenzhou, China[7]Qilu Hospital of Shandong University, Department of Rheumatology, Ji’nan, China[8]Jiangxi Pingxiang People’s Hospital, Department of Rheumatology, Pingxiang, China[9]China-Japan Friendship Hospital, Department of Rheumatology, Beijing, China[10]The First Affiliated Hospital of Bengbu Medical College, Department of Rheumatology, Bengbu, China[11]First Affiliated Hospital of Kunming Medical University, Department of Rheumatology, Kunming, China昆明医科大学附属第一医院[12]The First Hospital of Jilin University, Department of Rheumatology, Changchun, China[13]The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Department of Rheumatology, Baotou, China内蒙古科技大学包头医学院[14]The Second Affiliated Hospital Zhejiang University School of Medicine, Department of Rheumatology, Hangzhou, China[15]Nanjing Drum Tower Hospital, Department of Rheumatology, Nanjing, China[16]Zhongda Hospital Southeast University, Department of Rheumatology, Nanjing, China[17]Cangzhou Hospital of Integrated TCM-WM ・ Hebei, Department of Rheumatology, Cangzhou, China[18]Shanghai Henlius Biotech, Inc., Global Product Development, Shanghai, China
第一作者机构：[1]Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China
推荐引用方式(GB/T 7714)：
X. Zeng,J. Liu,X. Liu,et al.EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY[J].ANNALS OF THE RHEUMATIC DISEASES.2021,80:1122-1123.doi:10.1136/annrheumdis-2021-eular.282.
APA：
X. Zeng,J. Liu,X. Liu,L. Wu,Y. Liu...&Q. Wang.(2021).EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY.ANNALS OF THE RHEUMATIC DISEASES,80,
MLA：
X. Zeng,et al."EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY".ANNALS OF THE RHEUMATIC DISEASES 80.(2021):1122-1123
医学